In recent years, the debate over net price transparency (NPT) has intensified with organisations leading calls for greater transparency of net prices in the pharmaceutical sector. In a study funded by Merck Sharp & Dohme, an expert panel coordinated by CRA developed evidence on the impact of greater NPT on innovative medicines in Europe.
CRA leading the way in analytics
In recent years, the adoption of advanced treatments in inflammatory bowel disease has evolved. Oral products have captured a significant share in ulcerative...